ArticleInternational journal of clinical and experimental pathology2015
Demethylation of miR-10b plays a suppressive role in ccRCC cells.
Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 17 citations in OpenAlex.
- Sox2 induces glioblastoma cell stemness and tumor propagation by repressing TET2 and deregulating 5hmC and 5mC DNA modifications.Signal transduction and targeted therapy · 2022Article
- The critical role of BAP1 mutation in the prognosis and treatment selection of kidney renal clear cell carcinoma.Translational andrology and urology · 2020Article
- Integrative analysis of DNA methylation and gene expression in papillary renal cell carcinoma.Molecular genetics and genomics : MGG · 2020Article
- MicroRNA Signature in Renal Cell Carcinoma.Frontiers in oncology · 2020Review
- The potential role of miR-126, miR-21 and miR-10b as prognostic biomarkers in renal cell carcinoma.Oncology letters · 2019Article
- Molecular Mechanisms in Clear Cell Renal Cell Carcinoma: Role of miRNAs and Hypermethylated miRNA Genes in Crucial Oncogenic Pathways and Processes.Frontiers in genetics · 2019Review
- The Role of DNA Methylation in Renal Cell Carcinoma.Molecular diagnosis & therapy · 2018Review
- Non-blood circulating tumor DNA detection in cancer.Oncotarget · 2017Review
- MicroRNA-10b inhibits proliferation, migration and invasion in cervical cancer cells via direct targeting of insulin-like growth factor-1 receptor.Oncology letters · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs have been implicated in cancer cells proliferation, migration and invasion, including clear-cell renal cell carcinoma (ccRCC). DNA methylation, a major epigenetic change associated with cancer, may lead to transcriptional silencing of tumor suppressor genes, including miRNAs, which may be a possible mechanism in carcinogenesis. In this study, we aim to investigate the role of miR-10b in ccRCC and its possible epigenetic mechanism. By qPCR and MSP, we found that miR-10b was significantly decreased in ccRCC tissues and cells, and exhibited heavy methylation on promoter. Upregulation of miR-10b by transfecting with lentivirus highly expressed miR-10b or by exogenous demethylation agents was capable of inhibiting cell proliferation, migration and invasion measured by CCK-8 cell proliferation assay, scratch assay, transwell assay, and flow cytometric analysis of the cell cycle. Our results suggest that miR-10b plays a tumor-suppressive role in ccRCC. Demethylation of miR-10b may be therapeutically beneficial for ccRCC treatment.
Indexed as
Identifiers
26617769PMC4637584W2181839740What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.